What question did this study set out to answer?

This analysis aims to identify factors associated with serious adverse events following vaccination.

May 3, 2026Frontiers in Public Health0 citationsOpen Access

Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025

Key Points

This analysis aims to identify factors associated with serious adverse events following vaccination.
Analyzed 50,655 reports from the Vaccine Adverse Event Reporting System (VAERS) in 2025.
Categorized data into five domains: demographic characteristics, clinical features, medical history, vaccine variables, and patient outcomes.
Employed a multivariable logistic regression model to assess associations with SAE reporting.
9.58% of reported adverse events were classified as serious.
Advanced age (≥65 years, aOR: 1.73), male sex (aOR for females: 0.72), and longer onset times (aOR: 1.06) were linked with increased SAE reporting.
Non-intramuscular administration routes (oral aOR: 2.85; subcutaneous aOR: 1.51) were associated with higher odds of serious adverse events.

Abstract

Background and aims While vaccination is a vital and cost-effective public health tool, a small fraction of recipients experience serious adverse events (SAEs) that impose a profound clinical and systemic burden. Identifying the specific factors that predispose an individual to an SAE remains complex due to limitations in existing literature. This study analyzes SAE following immunization in the US population and identifies associated factors. Methods We analyzed a national cross-section of 50,655 reports submitted to the Vaccine Adverse Event Reporting System (VAERS) throughout 2025. Data were categorized into five domains: demographic characteristics, clinical features, medical history, vaccine variables, and patient outcomes. A multivariable logistic regression model was employed to identify factors associated with reporting SAEs. Results Of the 50,655 AEFIs reported (median age: 40 years), 9.58% were classified as SAEs. Multivariable analysis identified significant demographic and clinical factors associated with SAE reporting, including advanced age (≥65 years, aOR: 1.73), male sex (aOR for females: 0.72), longer onset times (aOR: 1.06), administration facilities (military, aOR: 1.76; private facilities, aOR: 1.39), and systemic symptoms (aOR: 1.72), while local symptoms were highly protective (aOR: 0.35). Patient history variables, such as current illness (aOR: 1.51) and medical history (aOR: 1.24), were associated with increased odds of SAE reporting, while prior reactions were protective (aOR: 0.77). Regarding vaccine characteristics, mRNA platforms (Pfizer/Wyeth aOR: 1.65), second doses (aOR: 1.33), non-intramuscular administration routes (oral aOR: 2.85; subcutaneous aOR: 1.51), and right-arm injections (aOR: 1.24) were all associated with higher odds of SAEs. Conclusion SAE reporting is driven by a complex intersection of demographic, clinical, and vaccine-related characteristics. These findings carry significant clinical and public health implications, highlighting the need for enhanced screening and proactive monitoring of high-risk populations to optimize global vaccine safety protocols. Future studies should integrate passive reporting with active surveillance to optimize vaccine safety protocols.

AI से पूछें

Bookmark

View Full Paper